Reven today announced that it has licensed intellectual property, technology and knowledge pertaining to multiple owned patents supported by a decade of pre-clinical and clinical research in anti-inflammatory effects of bio-similar nutrients to ENS … Read More
Reven today announced that it has licensed intellectual property, technology and knowledge pertaining to multiple owned patents supported by a decade of pre-clinical and clinical research in anti-inflammatory effects of bio-similar nutrients to ENS … Read More
Dear Shareholders, 2021 is now behind us and we, at Reven, continue to look forward. Despite the pandemic challenges that impacted all aspects of normal business operations, the Reven management team continues to prepare the company for the commercialization of its flagship drug, RJX. … Read More
Reven today announced the publication of a peer-reviewed article in the prestigious medical journal Frontiers in Oncology. The article reports a systematic analysis of the antibody responses to COVID-19 vaccination in cancer patients. This analysis … Read More
Reven today announced that the first patient has been dosed in the randomized, double-blind, placebo-controlled Part 2 portion of the Phase 2 study (ClinicalTrials.gov Identifier: NCT04708340 … Read More
Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Reven’s lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients … Read More
Yesterday co-founder Michael Volk appeared on Cheddar News (40 million pay-tv households) to discuss the future of medicine. In this national broadcasted interview, Mr. Volk shared the company’s goals to bring their flagship platform drug Rejuveinix (RJX) to market. … Read More
Michael Volk joins Cheddar News to discuss Reven Pharmaceuticals and RJX. … Read More
Reven today announced the publication of a peer-reviewed article in the prestigious medical journal, Biomedicine and Pharmacotherapy. In this new publication, Reven Pharmaceuticals team reports positive results regarding the safety and preclinical efficacy of a second generation formulation of its lead anti-sepsis drug candidate Rejuveinix (RJX). … Read More
Reven is pleased to announce the appointment of Daniel Hoffman as Chief Operating Officer, effective immediately. Mr. Hoffman will support co-founders Peter Lange, Michael Volk, and Brian Denomme in executing their vision in bringing the company’s flagship platform drug Rejuveinix (RJX) to market … Read More
Reven today announced that the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340 … Read More
Reven has launched its translational oncology program as a new drug discovery and development initiative that is aimed at changing the therapeutic landscape for difficult-to-treat forms of cancer. The overarching goal of this program is to treat cancer patients more effectively by altering the immediate surroundings of their tumor tissue, also known as the tumor microenvironment (TME). … Read More
We are happy to share the progress of Reven Holdings, Inc. (“Reven”) for the 2020 year. Despite an unprecedented global pandemic, 2020 was another year filled with major milestones for the company … Read More
Reven today announced the publication of a peer-reviewed article in the prestigious medical journal, Frontiers in Pharmacology, Section: Respiratory Pharmacology. In this new publication, the Reven Pharmaceuticals team reports positive results regarding the clinical safety and preclinical efficacy … Read More
Reven today announced the provisional acceptance and early online publication of a peer-reviewed article authored by its Chief Medical Officer & Chief Scientific Officer, Fatih Uckun M.D. Ph.D., and his academic collaborators in the medical journal, Frontiers in Nutrition … Read More
